Federated Hermes
TVTX icon

Federated Hermes’s Travere Therapeutics TVTX Stock Holding History

Federated Hermes’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.76M Buy
92,812
+24,513
+36% +$733K ﹤0.01% 907
2025
Q4 		$2.61M Buy
68,299
+51,588
+309% +$1.68M ﹤0.01% 910
2025
Q3 		$399K Sell
16,711
-510,827
-97% -$9.6M ﹤0.01% 1391
2025
Q2 		$7.81M Sell
527,538
-145,110
-22% -$2.41M 0.01% 621
2025
Q1 		$12.1M Buy
672,648
+4,333
+0.6% +$87.9K 0.03% 517
2024
Q4 		$11.6M Buy
668,315
+44,500
+7% +$787K 0.03% 520
2024
Q3 		$8.73M Buy
623,815
+582,098
+1,395% +$6.06M 0.02% 607
2024
Q2 		$343K Buy
+41,717
New +$281K ﹤0.01% 1391
2023
Q4 		– Sell
-97,491
Closed -$872K – 2213
2023
Q3 		$872K Buy
+97,491
New +$1.38M ﹤0.01% 1156
2023
Q1 		– Sell
-1
Closed -$21 – 2262
2022
Q4 		$21 Sell
1
-1,198
-100% -$25.4K ﹤0.01% 2141
2022
Q3 		$30K Buy
1,199
+419
+54% +$10.8K ﹤0.01% 1732
2022
Q2 		$20K Sell
780
-86,154
-99% -$2.17M ﹤0.01% 1768
2022
Q1 		$2.24M Buy
86,934
+35,822
+70% +$951K 0.01% 1010
2021
Q4 		$1.59M Buy
51,112
+47,971
+1,527% +$1.35M ﹤0.01% 1115
2021
Q3 		$76K Sell
3,141
-63,257
-95% -$1.16M ﹤0.01% 1809
2021
Q2 		$969K Sell
66,398
-248,419
-79% -$4.9M ﹤0.01% 1330
2021
Q1 		$7.86M Buy
314,817
+49,583
+19% +$1.37M 0.02% 731
2020
Q4 		$7.23M Buy
265,234
+196,422
+285% +$4.59M 0.01% 714
2020
Q3 		$1.27M Buy
68,812
+67,392
+4,746% +$1.31M ﹤0.01% 1158
2020
Q2 		$29K Sell
1,420
-88
-6% -$1.4K ﹤0.01% 1828
2020
Q1 		$22K Buy
+1,508
New +$22.7K ﹤0.01% 1779
2019
Q1 		– Sell
-98,485
Closed -$2.23M – 2231
2018
Q4 		$2.23M Buy
98,485
+4,990
+5% +$124K 0.01% 987
2018
Q3 		$2.69M Buy
93,495
+3,855
+4% +$110K 0.01% 993
2018
Q2 		$2.44M Buy
+89,640
New +$2.39M 0.01% 939

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Federated Hermes's TVTX Position: Q1 2026 in Review

Federated Hermes increased its Travere Therapeutics (TVTX) stake by 36% in Q1 2026, buying an estimated $733K and bringing the position to 92,812 shares worth $2.76M. The position accounts for ﹤0.01% of the portfolio, ranked #907.

Federated Hermes first reported a position in TVTX in Q2 2018 and has held it in 24 quarters since. The position peaked at $12.1M in Q1 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Federated Hermes held 92,812 shares of Travere Therapeutics worth $2.76M as of Q1 2026.
  • Federated Hermes bought 24,513 Travere Therapeutics shares in Q1 2026, an estimated $733K.
  • Travere Therapeutics made up ﹤0.01% of Federated Hermes's portfolio in Q1 2026, its #907 holding.
  • Federated Hermes first reported a position in Travere Therapeutics in Q2 2018 and has held it in 24 quarters since.
  • Federated Hermes's Travere Therapeutics position peaked at $12.1M in Q1 2025.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Federated Hermes's 13F filing for Q1 2026, filed 11 May 2026.